BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33761055)

  • 1. MRI characteristics in treatment for cerebral melanoma metastasis using stereotactic radiosurgery and concomitant checkpoint inhibitors or targeted therapeutics.
    Rauch M; Tausch D; Stera S; Blanck O; Wolff R; Meissner M; Urban H; Hattingen E
    J Neurooncol; 2021 May; 153(1):79-87. PubMed ID: 33761055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis.
    Hadi I; Roengvoraphoj O; Bodensohn R; Hofmaier J; Niyazi M; Belka C; Nachbichler SB
    Radiat Oncol; 2020 Feb; 15(1):37. PubMed ID: 32059731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment.
    Trommer-Nestler M; Marnitz S; Kocher M; Rueß D; Schlaak M; Theurich S; von Bergwelt-Baildon M; Morgenthaler J; Jablonska K; Celik E; Ruge MI; Baues C
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition.
    Le A; Mohammadi H; Mohammed T; Burney H; Zang Y; Frye D; Shiue K; Lautenschlaeger T; Miller J
    J Neurooncol; 2022 Jul; 158(3):481-488. PubMed ID: 35641840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study.
    Badrigilan S; Meola A; Chang SD; Rezaeian S; Nemati H; Almasi T; Rostampour N
    Br J Neurosurg; 2023 Dec; 37(6):1533-1543. PubMed ID: 34979828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
    Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
    J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis.
    Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Aizer AA; Rahman R; Guenette JP; Huang RY
    Eur Radiol; 2021 Jun; 31(6):4114-4129. PubMed ID: 33241519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
    Singh C; Qian JM; Yu JB; Chiang VL
    J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.
    Le Rhun E; Wolpert F; Fialek M; Devos P; Andratschke N; Reyns N; Regli L; Dummer R; Mortier L; Weller M
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32747372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes.
    Shanker MD; Garimall S; Gatt N; Foley H; Crowley S; Le Cornu E; Muscat K; Soon W; Atkinson V; Xu W; Watkins T; Huo M; Foote MC; Pinkham MB
    J Med Imaging Radiat Oncol; 2022 Jun; 66(4):536-545. PubMed ID: 35343063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma.
    Stera S; Balermpas P; Blanck O; Wolff R; Wurster S; Baumann R; Szücs M; Loutfi-Krauss B; Wilhelm ML; Seifert V; Rades D; Rödel C; Dunst J; Hildebrandt G; Arnold A; Meissner M; Kähler KC
    Melanoma Res; 2019 Apr; 29(2):187-195. PubMed ID: 30802230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis.
    Kotecha R; Kim JM; Miller JA; Juloori A; Chao ST; Murphy ES; Peereboom DM; Mohammadi AM; Barnett GH; Vogelbaum MA; Angelov L; Suh JH; Ahluwalia MS
    Neuro Oncol; 2019 Aug; 21(8):1060-1068. PubMed ID: 30796838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Monitoring of Immunotherapy and Targeted Therapy Using
    Galldiks N; Abdulla DSY; Scheffler M; Wolpert F; Werner JM; Hüllner M; Stoffels G; Schweinsberg V; Schlaak M; Kreuzberg N; Landsberg J; Lohmann P; Ceccon G; Baues C; Trommer M; Celik E; Ruge MI; Kocher M; Marnitz S; Fink GR; Tonn JC; Weller M; Langen KJ; Wolf J; Mauch C
    J Nucl Med; 2021 Apr; 62(4):464-470. PubMed ID: 32887757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
    Rauschenberg R; Bruns J; Brütting J; Daubner D; Lohaus F; Zimmer L; Forschner A; Zips D; Hassel JC; Berking C; Kaehler KC; Utikal J; Gutzmer R; Terheyden P; Meiss F; Rafei-Shamsabadi D; Kiecker F; Debus D; Dabrowski E; Arnold A; Garzarolli M; Kuske M; Beissert S; Löck S; Linn J; Troost EGC; Meier F
    Eur J Cancer; 2019 Mar; 110():11-20. PubMed ID: 30739835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis.
    Lu VM; Goyal A; Rovin RA; Lee A; McDonald KL
    J Neurooncol; 2019 Jan; 141(1):1-12. PubMed ID: 30392086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.
    Murphy B; Walker J; Bassale S; Monaco D; Jaboin J; Ciporen J; Taylor M; Dai Kubicky C
    Am J Clin Oncol; 2019 Mar; 42(3):253-257. PubMed ID: 30557166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.